Share on StockTwits

BioMarin Pharmaceutical (NASDAQ:BMRN) CFO Daniel K. Spiegelman sold 2,229 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $61.76, for a total value of $137,663.04. Following the transaction, the chief financial officer now directly owns 68,676 shares in the company, valued at approximately $4,241,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Nomura raised their price target on shares of BioMarin Pharmaceutical from $77.00 to $82.00 in a research note on Thursday. They now have a “neutral” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Friday, July 4th. They now have a $68.00 price target on the stock. Finally, analysts at Credit Suisse upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. They now have a $73.00 price target on the stock, up previously from $61.74. Nine equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $81.43.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 3.76% on Monday, hitting $64.28. 1,339,931 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a one year low of $55.04 and a one year high of $84.25. The stock has a 50-day moving average of $61.2 and a 200-day moving average of $65.60. The company’s market cap is $9.457 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Wednesday, July 30th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.18. The company had revenue of $191.70 million for the quarter, compared to the consensus estimate of $159.70 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 40.1% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.40 EPS for the current fiscal year.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.